Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06864884 · ClinicalTrials.gov registry record · Early Phase 1
A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction
A Early Phase 1 study of Acute Post Operative Pain and Third Molar Extraction Surgery, sponsored by Arcato Laboratories.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06864884: Recruiting Early Phase 1 study of Acute Post Operative Pain and Third Molar Extraction Surgery, sponsored by Arcato Laboratories.
NCT06864884 is a Early Phase 1 study of Acute Post Operative Pain and Third Molar Extraction Surgery that is actively recruiting participants, run by Arcato Laboratories. The registered enrollment target is 30 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06864884, a Early Phase 1 study of Acute Post Operative Pain and Third Molar Extraction Surgery, is actively recruiting participants, sponsored by Arcato Laboratories.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The study will test the investigational product gel against placebo (which contains no active ingredient) to determine if it is safe after wisdom tooth extraction. The main questions the study will answer are: 1. How much of the investigational product is absorbed in the blood? 2. Are there side effects?
Primary Outcome
To evaluate the safety and tolerability of ARC-001 Gel compared to placebo by comparing the incidence of oral treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) through oral exam for soft tissue health using the modified Landry Index and evaluation of the presence or absence of dry socket.
Conditions Studied
Interventions
- DRUG ARC-001
- DRUG Placebo gel
Study Locations (1)
Utah
- CenExel JBR - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-02-26 |
| Est. Completion | 2026-02 |
| Phase | Early Phase 1 |
What NCT06864884 shows while recruiting
NCT06864884 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower).
The record links to 2 conditions, with Acute Post Operative Pain appearing as the primary indexed condition, and to 2 interventions - of which ARC-001 is the first listed.
NCT06864884 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT06864884 about?
NCT06864884 is a clinical study titled "A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction". The study will test the investigational product gel against placebo (which contains no active ingredient) to determine if it is safe after wisdom tooth extraction. The main questions the study will answer are: 1. How much of the investigational product is absorbed in the blood? 2. Are there side ef...
What is the current status of trial NCT06864884?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-02-26. Estimated completion is 2026-02.
What conditions does trial NCT06864884 study?
This clinical trial studies the following conditions: Acute Post Operative Pain, Third Molar Extraction Surgery.
What interventions are being tested in trial NCT06864884?
The interventions under investigation include: ARC-001 (DRUG), Placebo gel (DRUG).
Who is sponsoring clinical trial NCT06864884?
This trial is sponsored by Arcato Laboratories, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06864884 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Post Operative Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06864884's enrollment target sits among peer trials
30 807th of 2000 higher than 1,075 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI